MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
New Facility Allows MedImmune to Meet Increasing Demands for Clinical Trial Materials from Company's Expanding and Advancing Pipeline
MedImmune unveiled a new, state-of-the-art pilot lab facility located on the same Gaithersburg site as its headquarters. With its cutting-edge equipment and process automation systems, the facility shall support MedImmune's expanding clinical product pipeline by providing additional capacity and flexibility.
The new pilot lab's 5,000 liters of bioreactor capacity will result in a four-fold increase in production capabilities. With the expanded facility, MedImmune will be able to produce clinical trial materials at a greater scale and in greater quantities, aiding in the testing of potential new products.
"This substantial increase in MedImmune's clinical production infrastructure supports our robust pipeline of product candidates," said Gail Folena-Wasserman, Ph.D., senior vice president, development. "The pilot lab facility is intended to meet our current and future needs, not just through its increased capacity but also through design flexibility, which efficiently allows us to produce multiple clinical products in the same space. We can drive efficiency and meet rigorous quality standards by incorporating the latest technology, including an advanced process control system."
Other news from the department manufacturing
